On November 12, ILUVATAR COREX rose 3.53% in regular trading, trading at HK$74.85, with turnover of HK$103 million.
The move coincided with continued market attention on the company’s recently disclosed TianGai 300 validation progress, with third-party testing indicating end-to-end throughput equivalent to 1.05 times a leading international mainstream GPU under a typical PD-separated deployment, while the IXL144 supernode was estimated to reduce cost per million effective tokens by about 40% versus mainstream international alternatives.
Additional disclosed operating metrics also provided context for investor focus: the company previously said cumulative chip shipments in the first 10 months exceeded 80,000 units, while first-half revenue reached RMB946 million, up 191.6% year over year. Together, product validation, cost competitiveness, and shipment growth form the main publicly available support for the stock’s continued strength.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments